Navigation Links
A More Convenient HIV Treatment Is as Effective as More Complex Regimens

Regimens to treat HIV infection that are based on a non-nucleoside reverse transcriptase inhibitor (NNRTI) are at least as effective as treatment with a protease inhibitor// but require patients to take fewer pills each day, according to a new study funded in part by HHS’ Agency for Healthcare Research and Quality.

The study, published in the October 28 online issue of the Lancet, found that disease progression was similar for both regimens, but NNRTI-based treatment appeared more effective at decreasing the amount of virus in the blood. The number of patients who stopped treatment because of adverse events was similar for both medications.

The new study is the first to review all published research that directly compares the two classes of antiretroviral drugs used in highly active antiretroviral therapy (HAART). NNRTI-based regimens were found to be up to 60 percent more likely to suppress the amount of virus in patients’ blood than protease inhibitor-based regimens. The percentage of patients who died or experienced disease progression were similar between the two treatments, and the number of patients who stopped taking the medications because of side effects or adverse events was also similar.

While some protease inhibitors require four doses each day, one NNRTI, efavirenz, can be taken in one daily dose. This convenience could increase the likelihood that patients will adhere to their HIV regimens.

Publication of the study follows the July 12 approval by the Food and Drug Administration of the first once-a-day medication to treat HIV. The drug contains emtricitabine and tenofovir, two nucleoside reverse transcriptase inhibitors, plus efavirenz. The components of the drug were previously available, but it is anticipated that the new combined formulation will simplify treatment and improve compliance.

"A simpler regimen offers the potential of improved adherence and better patient outcomes. Combined wit
'"/>




Page: 1 2 3

Related medicine news :

1. Inhalants: The New, Convenient High for Kids and Teens
2. Advances in Treatment of Cataracts
3. Recommendations for Treatment of Blood Pressue
4. Treatment for Menieres disease
5. Treatment for pre-menstrual syndrome is ineffective
6. Better Treatment for obesity
7. Gene Treatment for Heart Disease
8. More People Seeking Treatment for Depression
9. Focused Treatment For Childhood Cancer
10. Inadequate Drug Treatment For Youth
11. FDA Approves New surgery Treatment for Farsightedness
Post Your Comments:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 1Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 2Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 3Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 4Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 5StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 1StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 2StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 3StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 4National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 1National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 2National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 3National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 4